Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Halozyme Therapeutics to related businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
Valuation and Earnings
This table compares Halozyme Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Halozyme Therapeutics | $1.40 billion | $316.89 million | 23.67 |
| Halozyme Therapeutics Competitors | $718.90 million | $8.79 million | -18.37 |
Halozyme Therapeutics has higher revenue and earnings than its peers. Halozyme Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Halozyme Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Halozyme Therapeutics | 26.93% | 751.81% | 23.84% |
| Halozyme Therapeutics Competitors | -12,516.26% | -215.37% | -31.41% |
Risk and Volatility
Halozyme Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics’ peers have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Halozyme Therapeutics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Halozyme Therapeutics | 1 | 5 | 7 | 0 | 2.46 |
| Halozyme Therapeutics Competitors | 9926 | 15341 | 45743 | 1601 | 2.54 |
Halozyme Therapeutics presently has a consensus target price of $108.18, suggesting a potential upside of 16.27%. As a group, “Biotechnology” companies have a potential upside of 111.21%. Given Halozyme Therapeutics’ peers stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics has less favorable growth aspects than its peers.
Summary
Halozyme Therapeutics beats its peers on 8 of the 13 factors compared.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
